Eli Lily’s Sarcoma Newcomer Lartruvo Joins Burgeoning Oncology Lineup

On last Wednesday, October 19, the FDA approved Eli Lilly’s Lartruvo in combination with Doxorubicin for the treatment of adults with soft tissue sarcoma (STS). Lartruvo is the first monoclonal antibody approved to treat STS and this in combination with doxorubicin is the first FDA-approved front-line therapy for STS in four decades.

Lartruvo’s indication was approved under accelerated condition based on the result the positive Phase 2 JGDG trial. Soft tissue sarcoma is a deadly and complex disease with multiple subtypes, making it hard to diagnose and difficult to treat. Lartruvo will be a great alternative chemo therapy option for patients who can’t be treated with radiotherapy or surgery.

If you would like to read the full article:

http://www.fiercepharma.com/pharma/lilly-s-sarcoma-newcomer-lartruvo-joins-burgeoning-oncology-lineup

#EliLilly #oncology #Lartruvo